bevacizumab,oxaliplatin,trifluridine tipiracil,irinotecan,trifluridine tipiracil
ipsen,roche,taiho pharma,otsuka,pfizer
[]
 trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: @ asco-gi 2023 sunlight phs-iii, 492 pts, 75% prior bev mos 10.8 vs 7.5 mo mpfs 5.6 vs 2.4 mo proof for cont. anti-angiogenesis in #crc 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine